Singapore markets closed
  • Straits Times Index

    -32.69 (-0.99%)
  • Nikkei

    +727.65 (+2.62%)
  • Hang Seng

    +93.19 (+0.46%)
  • FTSE 100

    +36.18 (+0.48%)

    -470.60 (-1.93%)
  • CMC Crypto 200

    -1.60 (-0.28%)
  • S&P 500

    +37.04 (+0.88%)
  • Dow

    +202.55 (+0.61%)
  • Nasdaq

    +157.08 (+1.23%)
  • Gold

    +5.90 (+0.33%)
  • Crude Oil

    -2.01 (-2.13%)
  • 10-Yr Bond

    -0.0330 (-1.14%)
  • FTSE Bursa Malaysia

    +0.63 (+0.04%)
  • Jakarta Composite Index

    -31.11 (-0.43%)
  • PSE Index

    +18.98 (+0.28%)

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to two new employees to purchase an aggregate of 5,200 shares of SCYNEXIS common stock at a per share exercise price of $7.38, the closing trading price on November 30, 2021. The stock options were granted as material inducements to the new employees to accept SCYNEXIS’ offers of employment.

Each option has a ten-year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the employee’s first date of employment and the remainder vesting in equal monthly installments for thirty-six months thereafter, provided the employee continues to provide service to SCYNEXIS. The stock options were granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended, which was adopted by SCYNEXIS’ board of directors under Rule 5635(c)(4) for equity grants to induce new employees to enter into employment with SCYNEXIS.


SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit

Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting